SIGNIFICANCE: These data confirm the effectiveness of office-based vergence/accommodative therapy for improving the near point of convergence and positive fusional vergence in young adults with symptomatic convergence insufficiency within a double-masked longitudinal randomized clinical trial. PURPOSE: This study aimed to report changes in clinical signs and symptoms of convergence insufficiency from a randomized clinical trial evaluating the effectiveness of office-based vergence/accommodative therapy for young adults with symptomatic convergence insufficiency. METHODS: In this double-masked, randomized clinical trial, convergence insufficiency patients (n = 50; average age, 21 ± 3 years; range, 18 to 32 years) were randomized to either office-based vergence/accommodative therapy or office-based placebo therapy. Improvements in (1) near point of convergence, (2) positive fusional vergence, and (3) self-reported symptoms (Convergence Insufficiency Symptom Survey [CISS] score) were evaluated after twelve 1-hour sessions of treatment within the office comparing the results from the vergence/accommodative therapy and the placebo therapy groups. RESULTS: The mean near point of convergence improved by 6.0 and 3.1 cm in the vergence/accommodative and placebo therapy groups, respectively (mean difference of -2.9 cm; 95% confidence interval [CI], -4.6 to -1.0 cm; P < .01). The mean positive fusional vergence increased by 17.3 and 7.4Δ in the vergence/accommodative and placebo therapy groups, respectively (mean difference of 9.9Δ; 95% CI, 4.9 to 16.0Δ; P < .001). The mean CISS score improved by 12.4 and 10.1 points in the vergence/accommodative and placebo therapy groups, respectively (mean difference of 2.3 points; 95% CI, -8.3 to +4.6 points; P = .56). CONCLUSIONS: Our results demonstrate that office-based vergence/accommodative therapy is effective for improving the near point of convergence and positive fusional vergence in young adults with symptomatic convergence insufficiency. However, given that both treatment groups had a similar reduction in self-reported symptoms, we recommend that the CISS be revised if it is to be used as an outcome measure in future studies of convergence insufficiency.
SIGNIFICANCE: These data confirm the effectiveness of office-based vergence/accommodative therapy for improving the near point of convergence and positive fusional vergence in young adults with symptomatic convergence insufficiency within a double-masked longitudinal randomized clinical trial. PURPOSE: This study aimed to report changes in clinical signs and symptoms of convergence insufficiency from a randomized clinical trial evaluating the effectiveness of office-based vergence/accommodative therapy for young adults with symptomatic convergence insufficiency. METHODS: In this double-masked, randomized clinical trial, convergence insufficiency patients (n = 50; average age, 21 ± 3 years; range, 18 to 32 years) were randomized to either office-based vergence/accommodative therapy or office-based placebo therapy. Improvements in (1) near point of convergence, (2) positive fusional vergence, and (3) self-reported symptoms (Convergence Insufficiency Symptom Survey [CISS] score) were evaluated after twelve 1-hour sessions of treatment within the office comparing the results from the vergence/accommodative therapy and the placebo therapy groups. RESULTS: The mean near point of convergence improved by 6.0 and 3.1 cm in the vergence/accommodative and placebo therapy groups, respectively (mean difference of -2.9 cm; 95% confidence interval [CI], -4.6 to -1.0 cm; P < .01). The mean positive fusional vergence increased by 17.3 and 7.4Δ in the vergence/accommodative and placebo therapy groups, respectively (mean difference of 9.9Δ; 95% CI, 4.9 to 16.0Δ; P < .001). The mean CISS score improved by 12.4 and 10.1 points in the vergence/accommodative and placebo therapy groups, respectively (mean difference of 2.3 points; 95% CI, -8.3 to +4.6 points; P = .56). CONCLUSIONS: Our results demonstrate that office-based vergence/accommodative therapy is effective for improving the near point of convergence and positive fusional vergence in young adults with symptomatic convergence insufficiency. However, given that both treatment groups had a similar reduction in self-reported symptoms, we recommend that the CISS be revised if it is to be used as an outcome measure in future studies of convergence insufficiency.
Authors: Douglas E Widmer; Tamara S Oechslin; Chirag Limbachia; Marjean Taylor Kulp; Andrew J Toole; Nasser H Kashou; Nicklaus Fogt Journal: Optom Vis Sci Date: 2018-06 Impact factor: 1.973
Authors: Michael Rouse; Eric Borsting; G Lynn Mitchell; Susan A Cotter; Marjean Kulp; Mitchell Scheiman; Carmen Barnhardt; Annette Bade; Tomohiko Yamada; Tomohike Yamada Journal: Optom Vis Sci Date: 2009-04 Impact factor: 1.973
Authors: Jonathan M Holmes; Vivian M Manh; Elizabeth L Lazar; Roy W Beck; Eileen E Birch; Raymond T Kraker; Eric R Crouch; S Ayse Erzurum; Nausheen Khuddus; Allison I Summers; David K Wallace Journal: JAMA Ophthalmol Date: 2016-12-01 Impact factor: 7.389
Authors: Ingryd J Lorenzana; David A Leske; Sarah R Hatt; Trevano W Dean; Erin C Jenewein; Linda R Dagi; Casey J Beal; Yi Pang; Dashaini V Retnasothie; Christina A Esposito; S A Erzurum; Amy E Aldrich; Eric R Crouch; Zhuokai Li; Raymond T Kraker; Jonathan M Holmes; Susan A Cotter Journal: Optom Vis Sci Date: 2022-08-02 Impact factor: 2.106
Authors: Tara L Alvarez; Chang Yaramothu; Mitchell Scheiman; Arlene Goodman; Susan A Cotter; Kristine Huang; Angela M Chen; Matthew Grady; Anne E Mozel; Olivia E Podolak; Chris G Koutures; Christina L Master Journal: Vision Res Date: 2021-04-23 Impact factor: 1.984